^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | capecitabine (Thymidylate synthase inhibitor) + vinorelbine tartrate (Tubulin polymerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Vinorelbine soft capsule and capecitabine as maintenance therapy for advanced triple negative breast cancer after first-line chemotherapy: a randomized, open, non inferiority phase III clinical study
Excerpt:
...Pathology confirmed that hormone receptor (ER and PR) was negative and HER2 was negative in advanced breast cancer; If there are multiple pathological results, triple negative breast cancer is defined as the final subtype according to the pathological molecular subtype of the last biopsy. ...
Trial ID:
Source:
Title:
Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer.
Excerpt:
...Women with age not less than 18 years,Documented metastatic breast cancer previously untreated by chemotherapy,HER2 negative (assessed by 0-1 + IHC or 2+ IHC with FISH-) on the primary tumor or on metastatic site, At least one measurable lesion using the RECIST criteria, Karnofsky Performance Status not less than 70%,Life expectancy not less than 16 weeks, Adequate bone marrow, hepatic and renal functions....
Trial ID:
Less C2 evidence
Source:
Title:
207P - A doublet metronomic chemotherapeutic regimen with oral vinorelbine and capecitabine (mNC) in patients with metastatic HER2-negative breast cancer: A prospective phase 2 study in China.
Published date:
05/07/2023
Excerpt:
29 patients with HER2-negative MBC were enrolled. 17 patients received mNC as first-line chemotherapy , 12 patients received mNC as second-line and 1 patient received mNC as > second-line. The median follow-up time was 25.4 months. The CBR, ORR and DCR were 62.1%, 31.0% and 96.6%, respectively. The mPFS was 12.5 months (range, 1.1-28.1). 1-year PFS rate was 54.1%...A doublet metronomic chemotherapeutic regimen with oral mNC is a well-tolerated and effective anti-tumor regimen for HER2-negative MBC in China.
Trial ID:
Source:
Title:
Vinorelbine plus capecitabine in a heavily pretreated HER2 negative metastatic breast cancer patient population: MCEPASTEBIN.
Published date:
05/16/2018
Excerpt:
...women with human epidermal growth factor receptor (HER2) negative MBC treated with vinorelbine 22.5mg/m2 IV on day 1 and 8 combined with capecitabine 1 gram PO BID...Clinical benefit rate, defined as complete response, partial response or stable disease ≥ 6months, was 63.76%...Median progression free survival (PFS) time was 6.2 months and overall survival 35.47 months from start of VINOCAP therapy.
